Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 12/20 | 0.55 |
| ▸ | DRD4 | P21917 | 12/20 | 0.55 |
| ▸ | DRD3 | P35462 | 12/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | HTR1B | P28222 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6309842 | 0.87 | TDP1 (0.55) | DRD2DRD4DRD3TDP1TSHR | |
| SCHEMBL2022332 | 0.84 | DRD4 (0.62) | DRD2DRD4DRD3TDP1TSHR | |
| SCHEMBL14294277 | 0.83 | DRD2 (0.79) | DRD2DRD4DRD3KDM4ENPC1 | |
| SCHEMBL14269835 | 0.82 | DRD4 (0.51) | DRD2DRD4DRD3TSHRRAB9A | |
| SCHEMBL7917299 | 0.81 | DRD4 (0.74) | DRD2DRD4DRD3HTR1B | |
| SCHEMBL111168 | 0.80 | TDP1 (0.67) | TDP1TSHRKDM4ENPC1RAB9A | |
| SCHEMBL112238 | 0.80 | TSHR (0.67) | TDP1TSHRKDM4ENPC1RAB9A | |
| Diethylamine SCHEMBL1284722 | 0.79 | TDP1 (0.55) | TDP1TSHRKDM4ENPC1RAB9A | |
| SCHEMBL20687468 | 0.79 | DRD2 (0.51) | DRD2DRD4DRD3TSHRKDM4E | |
| SCHEMBL10388529 | 0.79 | KMT2A (0.56) | DRD2DRD4DRD3KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7282498-B2 | Substituted fused pyrroleoximes and fused pyrazoleoximes | NEUROGEN CORPORATION (US) | 2007-10-16 | — | — | US | claimed |
| US-20050059826-A1 | Substituted fused pyrroleoximes and fused pyrazoleoximes | NEUROGEN CORPORATION | 2005-03-17 | — | — | US | claimed |
| US-20040110778-A1 | Heterocyclic compounds as ligands of the GABAA receptor | YOHANNES DANIEL (US) | 2004-06-10 | — | — | US | claimed |
| EP-1326831-A1 | SUBSTITUTED FUSED PYRROLEIMINES AND PYRAZOLEIMINES | NEUROGEN CORPORATION (US) | 2003-07-16 | — | — | EP | claimed |
| EP-1325006-A2 | HETEROCYCLIC COMPOUNDS AS LIGANDS OF THE GABA A? RECEPTOR | NEUROGEN CORPORATION (US) | 2003-07-09 | — | — | EP | claimed |
| US-20030105081-A1 | Heterocyclic compounds as ligands of the GABAA receptor | PFIZER INC | 2003-06-05 | — | — | US | claimed |
| US-20020128236-A1 | Substituted fused pyrroleoximes and fused pyrazoleoximes | NEUROGEN CORPORATION | 2002-09-12 | — | — | US | claimed |
| WO-2002020480-A1 | SUBSTITUTED FUSED PYRROLEIMINES AND PYRAZOLEIMINES | NEUROGEN CORPORATION (US) | 2002-03-14 | — | — | WO | claimed |
| WO-2002012442-A2 | HETEROCYCLIC COMPOUNDS AS LIGANDS OF THE GABAA RECEPTOR | NEUROGEN CORPORATION (US) | 2002-02-14 | — | — | WO | claimed |
| US-20090023737-A1 | Imidazo-Pyridazines, Triazolo-Pyridazines and Related Benzodiazepine Receptor Ligands | NEUROGEN CORPORATION (US) | 2009-01-22 | — | — | US | disclosed |
| US-20080167324-A1 | Thiazolymethyl and Oxazolylmethyl Heteroaryl Derivatives | NEUROGEN CORPORATION | 2008-07-10 | — | — | US | disclosed |
| US-20080139580-A1 | IMIDAZO-PYRIMIDINES AND TRIAZOLO-PYRIMIDINES: BENZODIAZEPINE RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080132510-A1 | Imidazolylmethyl and Pyrazolylmethyl Heteroaryl Derivatives | NEUROGEN CORPORATION | 2008-06-05 | — | — | US | disclosed |
| US-20080032975-A1 | Substituted Fused Pyrroleoximes and Fused Pyrazoleoximes | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE (US) | 2008-02-07 | — | — | US | disclosed |
| US-20040220253-A1 | Synthesis of pyrrole amides | PFIZER INC. | 2004-11-04 | — | — | US | disclosed |
| US-6743817-B2 | AGONISTS, ANTAGONISTS OR INVERSE AGONISTS FOR BRAIN RECEPTORS; ANXIOLYTICS, ANTIDEPRESSANTS, TREATING SLEEP AND PSYCHOLOGICAL DISORDERS | NEUROGEN CORPORATION | 2004-06-01 | — | — | US | disclosed |
| US-6653471-B2 | Tricyclic heteroaromatic compounds containing pyrrole ring; central nervous system disorder treatment; side effect reduction | NEUROGEN CORPORATION | 2003-11-25 | — | — | US | disclosed |
| EP-1339681-A1 | SYNTHESIS OF FUSED PYRROLECARBOXAMIDES | Pfizer Products Inc. (US) | 2003-09-03 | — | — | EP | disclosed |
| US-20020151718-A1 | Synthesis of pyrrole amides | PFIZER INC. | 2002-10-17 | — | — | US | disclosed |
| WO-2002046155-A1 | SYNTHESIS OF FUSED PYRROLECARBOXAMIDES | PFIZER PRODUCTS INC. (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105081-A1 | Heterocyclic compounds as ligands of the GABAA receptor | GABRB1, GABRP, GABRA1 | DRD2 379/4885DRD4 928/4885DRD3 523/4885 |
| US-20080132510-A1 | Imidazolylmethyl and Pyrazolylmethyl Heteroaryl Derivatives | GABRR3, GABRA3, GABRR1 | DRD2 187/4885DRD4 551/4885DRD3 177/4885 |
| US-20040220253-A1 | Synthesis of pyrrole amides | GABRA5, GABRA2, GABRA1 | DRD2 170/4885DRD4 493/4885DRD3 505/4885 |
| US-20050059826-A1 | Substituted fused pyrroleoximes and fused pyrazoleoximes | NPSR1, GABRE, CHRNE | DRD2 135/4885DRD4 292/4885DRD3 214/4885 |
| US-20020128236-A1 | Substituted fused pyrroleoximes and fused pyrazoleoximes | HTR1A, GABRA1, GABRE | DRD2 123/4885DRD4 297/4885DRD3 205/4885 |
| US-20020151718-A1 | Synthesis of pyrrole amides | GABRA5, GABRA2, GABRA1 | DRD2 170/4885DRD4 493/4885DRD3 505/4885 |
| US-20040110778-A1 | Heterocyclic compounds as ligands of the GABAA receptor | GABRB1, GABRP, GABRA1 | DRD2 379/4885DRD4 928/4885DRD3 523/4885 |
| US-20090023737-A1 | Imidazo-Pyridazines, Triazolo-Pyridazines and Related Benzodiazepine Receptor Ligands | GABRA4, GABRA2, GABRA5 | DRD2 171/4885DRD4 295/4885DRD3 236/4885 |
| US-20080139580-A1 | IMIDAZO-PYRIMIDINES AND TRIAZOLO-PYRIMIDINES: BENZODIAZEPINE RECEPTOR LIGANDS | GABRA3, GABRA1, GABBR1 | DRD2 197/4885DRD4 375/4885DRD3 175/4885 |
| US-20080032975-A1 | Substituted Fused Pyrroleoximes and Fused Pyrazoleoximes | NPSR1, GABRE, CHRNE | DRD2 135/4885DRD4 292/4885DRD3 214/4885 |
| US-20080167324-A1 | Thiazolymethyl and Oxazolylmethyl Heteroaryl Derivatives | GABBR1, GABBR2, GABRA3 | DRD2 706/4885DRD4 1598/4885DRD3 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.